U.S. Marine and Shipping Stock News

The recent move in Arcutis Biotherapeutics (ARQT) comes after the FDA accepted a supplemental application for ZORYVE cream 0.05%, which could extend its use to infants with mild to moderate atopic dermatitis. See our latest analysis for Arcutis Biotherapeutics. Against this backdrop, Arcutis Biotherapeutics’ recent 1-month share price return of 8.66% and 90-day share price return of 16.14% suggest improving momentum, while the year-to-date share price return has slightly declined 1.76%. Over...

Apollo Global Management (APO) has moved into the spotlight after easyJet backed its surprise takeover offer, valuing the airline at about £5.7b and setting up a bidding contest with rival suitor Castlelake. See our latest analysis for Apollo Global Management. Beyond the EasyJet bid, Apollo Global Management has been busy on the deal front. It recently closed the acquisitions of Emerald Holding and Questex and combined them into a single B2B events and media platform. This comes at a time...

Recent analyst coverage has pushed Cheesecake Factory (CAKE) into focus for growth oriented investors, highlighting favorable growth scores and a track record of positive earnings surprises ahead of its late July 2026 earnings report. See our latest analysis for Cheesecake Factory. The recent 36.84% 3 month share price return and 62.41% year to date share price return to about $85.77 suggest momentum has been building around Cheesecake Factory as investors react to its earnings track record...

Collegium Pharmaceutical stock has delivered a 59.6% total return over the past three years, yet its current checks point to pricing that looks broadly in line with the market rather than clearly cheap or clearly expensive. The 59.6% three year return suggests investors who stayed invested in Collegium Pharmaceutical have been rewarded, which raises the bar for what the current share price needs to justify. Future expectations for Collegium Pharmaceutical's revenue growth and cash generation...

Calumet (CLMT) is back on investors’ radar after Calumet Specialty Products Partners and Calumet Finance Corp. moved to redeem all $100 million of their 9.75% Senior Notes due 2028 at a premium in mid July. See our latest analysis for Calumet. The redemption news comes as Calumet’s share price trades at $42.83, with a 1 day share price return of 4.26% and a 30 day share price return of 29.20%. This has contributed to a stronger year to date share price return of 119.08% and a 1 year total...

Ecolab stock has delivered a 48.8% total return over the past three years, and at around US$272.83 per share the key question is whether that run now leaves it trading close to its intrinsic value or at a premium. The Discounted Cash Flow (DCF) estimate points to Ecolab being roughly fairly valued, while the broader valuation checks and market multiples lean more cautious. Ecolab's 48.8% return over three years means anyone who stayed invested has been rewarded, so fresh buyers now need to...

In July 2026, General Mills, ADM and Walmart announced a collaboration to expand regenerative agriculture across 40,000 Midwest wheat acres, offering farmers technical support and financial incentives to adopt practices such as no-till and cover crops. This three-way effort links ADM’s role as a major wheat supplier and manager of nearly 5 billion regenerative acres globally with large downstream buyers, creating a proof-of-concept for scaling sustainability across an integrated food supply...

RBC Capital recently downgraded ResMed to Sector Perform from Outperform, pointing to FY27 pressures from Astral ventilator replacements, higher input costs, and supply constraints on key components. The downgrade highlights how operational issues in a single product line can ripple through device sales, cost structure, and overall business planning for the coming years. Next, we’ll examine how expected FY27 cost pressures and supply bottlenecks may influence ResMed’s previously optimistic...

Ichor Holdings (ICHR) has drawn investor attention after recent share price moves, with the stock down 1.0% over the past day and 17.4% over the past week, following a period of strong multiyear total returns. See our latest analysis for Ichor Holdings. Zooming out, Ichor Holdings has seen its recent momentum fade, with the share price down 7.4% over the past month and 17.4% over the past week. However, the year to date share price return of 306.0% and 1 year total shareholder return of...

Resideo Technologies has nearly doubled investors' money over the past three years, and the current valuation checks suggest the stock still trades at a discount, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating room above the recent US$35.83 share price. Resideo Technologies has returned 98.4% over the past three years, which puts extra focus on whether that gain is fully backed by fundamentals. The planned spin off of the ADI Global Distribution business may support...

Voter support is tilting toward democratic socialist policies like universal healthcare, higher taxes on the wealthy, and more government-backed services, and that puts parts of the healthcare sector squarely under the spotlight. For investors, the bigger question is how potential future reforms and tougher oversight could affect margins, pricing power, and long term business models. This article examines the political catalysts behind this shift and then outlines 3 healthcare stocks that...

Assurant stock has delivered a strong 124.2% return over the past three years, yet the valuation picture is split, with the Excess Returns intrinsic value estimate pointing to meaningful upside while market multiples suggest the shares trade at a premium. Over three years, Assurant has returned 124.2%, which puts extra focus on whether today’s price still leaves room for attractive risk adjusted returns. Upcoming earnings, where analysts expect pressure on EPS, may influence views on the...

Earlier in July 2026, U.S. regulators expanded approval of Vertex’s gene-editing therapy Casgevy to children as young as 2 with sickle cell disease or transfusion-dependent thalassemia, while Canada’s pan-Canadian Pharmaceutical Alliance signed a Letter of Intent with Vertex to enable public reimbursement discussions for its cystic fibrosis therapy ALYFTREK. These moves deepen Vertex’s reach in severe genetic diseases by both widening the eligible patient pool for Casgevy and advancing payer...

S&P Global stock has delivered a 5 year return of 18.8%, yet its valuation checks currently lean expensive, which raises the question of how much of the story around new products and operating changes is already reflected in the US$450.84 share price. That 18.8% return over five years suggests S&P Global has rewarded patient shareholders, but not at a pace that clearly justifies paying any price for future growth. New offerings such as ETF Intelligence and a refreshed Market Intelligence...

Ameris Bancorp (ABCB) heads into its next earnings report on July 23 with expectations for higher year over year earnings and revenue, putting fresh attention on how the stock prices in those forecasts. See our latest analysis for Ameris Bancorp. The recent 7 day share price return of 2.10% and 30 day share price return of 7.32% suggest momentum has been building in Ameris Bancorp ahead of its earnings update. At the same time, the 1 year total shareholder return of 38.48% and 3 year total...

FMC (FMC) stock is in focus after the company submitted its first regulatory dossier for the new herbicide rimisoxafen to the U.S. Environmental Protection Agency, marking the compound’s initial global filing. See our latest analysis for FMC. Despite the positive headlines around rimisoxafen, FMC’s recent trading tells a different story, with the share price down 34.7% over 90 days and the 1 year total shareholder return declining 72.4%. This points to fading momentum as investors reassess...

Target Hospitality stock has delivered a very large 359.6% total return over the past five years, yet the current valuation checks lean expensive, with a low overall value score and market multiples that screen as overvalued. A 359.6% five year return means long term shareholders have already seen substantial gains, so fresh buyers are coming in after a strong run. Future contract wins and utilization levels can support earnings and cash flow, but any disappointment in occupancy or pricing...

Tradeweb Markets (TW) is back in focus after reporting June and second quarter 2026 operating metrics that show sharply higher trading activity, alongside a move to supply institutional bond pricing into the Pyth Network’s digital and onchain ecosystem. See our latest analysis for Tradeweb Markets. Despite the strong June and second quarter trading metrics, Tradeweb Markets’ recent share price return has been weak, with the stock down over the past quarter and year to date. However, the three...

Trump Media & Technology Group’s plan to charge up to US$100,000 per month for high speed API access to President Trump’s Truth Social posts is turning market information itself into a premium product. When a single message can jolt the S&P 500, oil prices, or individual stocks, the gap between traders who see that data first and everyone else can matter. This article looks at three stocks exposed to this new pay to see model, with one potentially positioned on the right side of the trend and...

Sticky inflation, a firm jobs market, and a Federal Reserve that signals it may keep policy tight or even tighten further all put a spotlight on companies tied to AI infrastructure and data centers. Capital spending linked to AI could both support earnings potential and add fresh inflation pressure, so stock selection matters. This article looks at how those macro forces intersect with AI related demand, and highlights three stocks with positive exposure from our AI Infrastructure and Data...

Salesforce stock has dropped 34.4% over the past year even as broader valuation checks still suggest the shares lean cheap. This puts the current price in the middle of a tug-of-war between weak recent returns and a relatively supportive valuation profile. Over the last 12 months, Salesforce is down 34.4%, a drawdown that has reset expectations and pushed investors to reassess what a reasonable entry price looks like. On one side, large AI related investments and mixed sentiment around the...

Eton Pharmaceuticals has turned heads with a very large 3 year return and a fresh 52 week run, yet its current checks paint a picture of a stock that screens as expensive rather than a clear bargain. Over the past 3 years, Eton Pharmaceuticals has delivered a very large total return of about 13x. This puts extra focus on whether recent optimism has already been reflected in the share price. Recent momentum around a new FDA approved drug agreement can support expectations for future revenue...

Digital Turbine stock has rebounded strongly in the short term, yet the valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value pointing to a premium while market multiples suggest the shares may be on the cheap side. Over the past 5 years the share price has declined about 86.9%, which leaves recent gains set against a much weaker longer term record for investors who held through the period. Expectations for Digital Turbine to sustain and convert its revenue...

Cleveland-Cliffs stock is coming off a difficult stretch, with the share price down 57.0% over the past 5 years, yet both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and conventional market multiples currently point to the shares trading below what the underlying cash flows may justify. The 57.0% share price decline over 5 years leaves existing holders with a steep loss, while raising the question of whether expectations have swung too far to the pessimistic...